New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid

References

• World Health OrganisationGlobal Tuberculosis Report 2014Geneva, SwitzerlandWorld Health Organization2014 Available from: http://www.who.int/tb/publications/global_report/en/Accessed July 11, 2015
   Google Scholar
• World Health OrganisationTowards Universal Access to Diagnosis and Treatment of Multidrug-resistant and Extensively Drug-resistant Tuberculosis by 2015: WHO Progress Report 2011Geneva, SwitzerlandWorld Health Organization2011
   Google Scholar
• World Health OrganisationGlobal Tuberculosis Report, Supplement Drug Resistant TB, Surveillance and ResponseGeneva, SwitzerlandWorld Health Organization2014 doi: WHO/HQ/TB/2014.12
   Google Scholar
• World Health OrganisationWHO End TB StrategyGenevaWorld Health Organization Available from: http://www.who.int/tb/post2015_strategy/en/Accessed July 11, 2015
   Google Scholar
• European Medicines Agency C for MP for HUEuropean Medicines Agency: Assessment Report: DeltybaLondon, EnglandEuropean Medicines Agency C for MP for HU2013 Procedure No EMEA/H/C/002552. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002552/smops/Positive/human_smop_000572.jsp&mid=WC0b01ac058001d127Accessed July 11, 2015
   Google Scholar
• European Medicine AgencySituroLondon, EnglandEuropean Medicine Agency Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/12/news_detail_001999.jsp&mid=WC0b01ac058004d5c1
   Google Scholar
• Food and Drug AdministrationSirturo (bedaquiline) Product InsertSilver Spring MDFood and Drug Administration Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdfAccessed July 11, 2015
   Google Scholar
• DooleyKEObukuEADurakovicNBelitskyVMitnickCNuer-mbergerELWorld Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?J Infect Dis201320791352135810.1093/infdis/jis46022807518
   PubMed Web of Science ®Google Scholar
• PadayatchiNClofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort studyJ Antimicrob Chemother2014691131033107 doi: 101093/jac/dku23524986495
   PubMed Web of Science ®Google Scholar
• GopalMPadayatchiNMetcalfeJZO’DonnellMRSystematic review of clofazimine for the treatment of drug-resistant tuberculosisInt J Tuberc Lung Dis20131781001100710.5588/ijtld.12.014423541151
   PubMed Web of Science ®Google Scholar
• GlerMTSkripconokaVSanchez-GaravitoEDelamanid for multidrug-resistant pulmonary tuberculosisN Engl J Med2012366232151216010.1056/NEJMoa111243322670901
   PubMed Web of Science ®Google Scholar
• SkripconokaVDanilovitsMPehmeLDelamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosisEur Respir J20134161393140010.1183/09031936.0012581223018916
   PubMed Web of Science ®Google Scholar
• SzumowskiJDLynchJBProfile of delamanid for the treatment of multidrug-resistant tuberculosisDrug Des Devel Ther2015967768210.2147/DDDT.S60923
   PubMed Web of Science ®Google Scholar
• Otsuka Pharmaceutical Development and Commercialization, IncSafety and efficacy trial of delamanid for 6 months in patients with multidrug resistant tuberculosis (NCT1424670) Available from: https://clinicaltrials.gov/ct2/show/NCT1424670Accessed July 11, 2015
   Google Scholar
• MatteelliACarvalhoACCDooleyKETMC207: the first compound of a new class of potent anti-tuberculosis drugsFuture Microbiol20105684985820521931
   PubMed Web of Science ®Google Scholar
• DiaconAHPymAGrobuschMPMultidrug-resistant tuberculosis and culture conversion with bedaquiline for the TMC207-C208 study group*N Engl J Med201483712172373210.1056/NEJMoa131386525140958
   PubMed Web of Science ®Google Scholar
• Treatment Action GroupHIV-HCV- TB Pipeline ReportNew York, NYTreatment Action Group2014
   Google Scholar
• Otsuka Pharmaceutical Development and Commercialization, Inc.A 6-month safety, efficacy, and pharmacokinetic trial of delamanid in pediatric patients with multidrug resistant tuberculosis (NCT1859923) Available from: http://clinicaltrials.gov/show/NCT1859923Accessed July 11, 2015
   Google Scholar
• World Health OrganisationWHO interim guidance on the use of bedaqui-line to treat MDR-TBGeneva, SwitzerlandWorld Health Organisation2013 Available from: http://www.who.int/mediacentre/news/notes/2013/bedaquiline_mdr_tb_20130613/en/Accessed July 11, 2015
   Google Scholar
• World Health OrganisationThe Use of Delamanid in the Treatment of Multidrug-Resistant TuberculosisGeneva, SwitzerlandWorld Health Organisation2014 Available from: http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf?ua=1Accessed July 11, 2015
   Google Scholar
• World Health OrganisationCompanion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant TuberculosisGeneva, SwitzerlandWorld Health Organisation2014 Available from: http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf?ua=1&ua=1Accessed July 11, 2015
   Google Scholar
• World Health OrganisationWorld Health Organisation Prequalification. WHO PrequalificationGeneva, SwitzerlandWorld Health Organisation2012 Available from: http://apps.who.int/prequal/query/Product-Registry.aspx?list=allAccessed July 11, 2015
   Google Scholar
• DeyTBrigdenGCoxHShubberZCookeGFordNOutcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysisJ Antimicrob Chemother201368228429310.1093/jac/dks38923054996
   PubMed Web of Science ®Google Scholar
• JagannathCReddyMVKailasamSO’SullivanJFGangadharamPRChemotherapeutic activity of clofazimine and its analogs against mycobacterium tuberculosis. In vitro, intracellular, and in vivo studiesAm J Respir Crit Care Med19951514108310867697235
   PubMed Web of Science ®Google Scholar
• AungKJMVan DeunADeclercqESuccessful “9-month Bangladesh regimen” for multidrug- resistant tuberculosis among over 500 consecutive patientsInt J Tuberc Lung Dis201418101180118710.5588/ijtld.14.010025216831
   PubMed Web of Science ®Google Scholar
• PiubelloAHarounaSHSouleymaneMBHigh cure rate with standardised short-course multidrug- resistant tuberculosis treatment in Niger: no relapsesInt J Tuberc Lung Dis201418101188119410.5588/ijtld.13.007525216832
   PubMed Web of Science ®Google Scholar
• NunnAJRusenIVan DeunAEvaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trialTrials201415353 Available from: http://www.trialsjournal.com/content/15/1/353Accessed July 11, 201525199531
   PubMed Web of Science ®Google Scholar
• DiaconSMDawsonRNiekerkCV14 Day EBA Study of PA-824 bedaquiline *pyrazinamide and clofazimine in smear positive TB patientsCROI2014Boston, MA Available from: http://www.croiconference.org/sessions/14-day-eba-study-pa-824-bedaquiline-pyrazinamide-and-clofazimine-smear-positive-tb-patientsAccessed July 11, 2015
   Google Scholar
• GrossetJHSingerTGBishaiWRGrossetJHNew drugs for the treatment of tuberculosis: hope and realityInt J Tuberc Lung Dis20121681005101410.5588/ijtld.12.027722762423
   PubMed Web of Science ®Google Scholar
• CoxHFordNLinezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysisInt J Tuberc Lung Dis201216444745410.5588/ijtld.11.045122325685
   PubMed Web of Science ®Google Scholar
• DhedaKSheanKZumlaAEarly treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort studyLancet201037597281798180710.1016/S0140-6736(10)60492-820488525
   PubMed Web of Science ®Google Scholar
• LeeMLeeJCarrollMWLinezolid for treatment of chronic extensively drug-resistant tuberculosisN Engl J Med201236715081518 Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1201964Accessed July 11, 201523075177
   PubMed Web of Science ®Google Scholar
• ChambersHFTurnerJSchecterGFKawamuraMHopewellPCImipenem for treatment of tuberculosis in mice and humansAnti-microb Agents Chemother20054972816282110.1128/AAC.49.7.2816-2821.2005
   PubMed Web of Science ®Google Scholar
• De LorenzoSAlffenaarJWSotgiuGEfficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TBEur Respir J20134161386139210.1183/09031936.0012431222997218
   PubMed Web of Science ®Google Scholar
• Médecins Sans Frontières Access CampaignReady set slow down. [Issue brief] Available from: https://www.msfaccess.org/sites/default/files/MSF_assets/TB/Docs/MSF_IssueBrief_DRTB_ReadySetSlowdown.pdfAccessed July 11, 2015
   Google Scholar
• GuglielmettiLLe DûDJachymMCompassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohortClin Infect Dis201560218819410.1093/cid/ciu78625320286
   PubMed Web of Science ®Google Scholar
• NdjekaNConradieFSchnippelKTreatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysisInt J Tuberc Lung Dis201519897998526162365
   PubMed Web of Science ®Google Scholar
• YeghiazaryanLArmenian experience on treatment of XDR and pre-XDR patients with new drugs under compassionate use programPresented at: Tuberculosis Symposium – Eastern Europe and Central AsiaFebruary 17–18, 2015 Available at: http://www.tb-symposium.org/documents/en/presentations/Lusine_Yeghiazaryan_BDQ_practical_use_eng.pdfAccessed July 11, 2015
   Google Scholar
• KeshavjeeSGelmanovaIYFarmerPETreatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort studyLancet200837296471403140910.1016/S0140-6736(08)61204-018723218
   PubMed Web of Science ®Google Scholar
• PietersenEIgnatiusEStreicherEMLong-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort studyLancet201438399241230123910.1016/S0140-6736(13)62675-624439237
   PubMed Web of Science ®Google Scholar
• KurbatovaEVTaylorAGamminoVMPredictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projectsTuberculosis201292539740322789497
   PubMed Web of Science ®Google Scholar
• JohnstonJCShahidiNCSadatsafaviMFitzgeraldJMTreatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysisPLoS One200949e691410.1371/journal.pone.000691419742330
   PubMed Web of Science ®Google Scholar
• HoltzTHSternbergMKammererSTime to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcomeAnn Intern Med20061449650659 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16670134Accessed July 11, 201216670134
   PubMed Web of Science ®Google Scholar
• O’DonnellMRPadayatchiNKvasnovskyCWernerLMasterIHorsburghCRTreatment outcomes for extensively drug-resistant tuberculosis and HIV co-infectionEmerg Infect Dis201319341642410.3201/eid1903.12099823622055
   PubMed Web of Science ®Google Scholar
• BonnetMEffectiveness of the WHO regimen for treatment of multi-drug resistant tuberculosisPresented at: European Respiratory Society Annual Congress2013 Available from: http://erj.ersjournals.com/content/42/Suppl_57/190.shortAccessed July 11, 2015
   Google Scholar
• BrigdenGNyang’waB-TDu CrosPPolicy and practice principles for designing future regimens for multidrug-resistant tuberculosisBull World Heal Organ201492687410.2471/BLT.13.122028
   Web of Science ®Google Scholar
• SotgiuGCentisRD’AmbrosioLEfficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysisEur Respir J20124061430144210.1183/09031936.0002291222496332
   PubMed Web of Science ®Google Scholar
• SchecterGFScottCTrueLRafteryAFloodJMaseSLinezolid in the treatment of multidrug-resistant tuberculosisClin Infect Dis2010501495510.1086/64867519947856
   PubMed Web of Science ®Google Scholar
• JachymMBedaquiline: practical use and interim results in France4th Tuberculosis Symposium for Central Asia and Eastern EuropeYerevan, ArmeniaFebruary 17–18, 2015
   Google Scholar
• Centre for Disease Control UProvisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis, 2013 Available from: http://www.cdc.gov/mmwr/cme/conted.htmlAccessed March 01, 2015
   Google Scholar
• Bedaquiline (Sirturo): Summary of Product CharacteristicsEuropean Medicines Agency Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002614/human_med_001730.jsp&mid=WC0b01ac058001d124Accessed March 01, 2015
   Google Scholar
• World Health OrganisationIntroduction of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis at Country Level: Implementation PlanGeneva, SwitzerlandWorld Health Organization2015 Available from: http://www.who.int/tb/publications/WHO_BDQimplementationplan.pdfAccessed July 11, 2015
   Google Scholar
• ERS/WHO Tuberculosis Consilium [homepage on the Internet] Available from: https://www.tbconsilium.org/Accessed July 11, 2015
   Google Scholar
• BriasoulisAAgarwalVPierceWJQT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medicationsCardiology20111202210311022156660
   PubMed Web of Science ®Google Scholar
• ShimokawaYSasaharaKYodaNMizunoKUmeharaKDelamanid does not inhibit or induce cytochrome p450 enzymes in vitroBiol Pharm Bull201437111727173525366478
   PubMed Web of Science ®Google Scholar
• PaccalyAJPetersenCPatilSAbsence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects19th International AIDS Conference 2012Washington DC
   Google Scholar
• HartkoornRCUplekarSColeSTCross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in mycobacterium tuberculosisAntimicrob Agents Chemother20145852979298110.1128/AAC.00037-1424590481
   PubMed Web of Science ®Google Scholar
• SomoskoviAA mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatmentEur Respir Soc J2015452554557
   PubMed Web of Science ®Google Scholar
• Global Drug Facility. GDF Impact on SLD Dynamics: 2011 vs 2013 Treatment Cost ComparisonPresentation 2014 Available at: http://www.stoptb.org/assets/documents/gdf/whatis/SecondLineDrugs.pdfAccessed July 11, 2015
   Google Scholar
• Médecins Sans FrontièresUnder the Microscope3rd edParis, FranceMédecins Sans Frontières2013
   Google Scholar
• USAIDUSAID and Johnson & Johnson to tackle antibiotic resistant TB Available from: http://www.usaid.gov/news-information/press-releases/dec-11-2014-usaid-and-johnson-johnson-tackle-antibiotic-resistant-tuberculosisAccessed July 11, 2015
   Google Scholar
• Tuberculosis (TB) An initiative to extend access to a new TB drugWorld Health Organization Available from: http://www.who.int/tb/features_archive/otsuka_2015/en/Accessed July 11, 2015
   Google Scholar
• RESIST-TB DR-TB Clinical Trial Progress Report Updated May 2015. Available from: http://www.resisttb.org/?page_id=1602Accessed July 11, 2015
   Google Scholar